Results 151 to 160 of about 16,210 (237)

Poly(ADP-ribose) polymerase-1 affects vasopressin-mediated AQP2 expression in collecting duct cells of the kidney.

Am J Physiol Renal Physiol
Jang HJ, Park E, Jung HJ, Kwon TH.
europepmc   +1 more source

Molecular mechanics calculations on deaminooxytocin and on deamino-arginine-vasopressin and its analogues

Journal of Computer-Aided Molecular Design, 1989
The backbone conformations of the cyclic moieties of 1-[beta-mercaptopropionic acid]-oxytocin [( Mpa1]-OT), [1-beta-mercaptopropionic acid]-arginine-vasopressin [( Mpa1]-AVP), [1-(beta'-mercapto-beta,beta-cyclopentamethylene)propionic acid]-arginine-vasopressin [( Cpp1]-AVP), and [1-thiosalicylic acid]-arginine-vasopressin [( Ths1]-AVP) have been ...
Adam Liwo, Anna Tempczyk, Zbigniew Grzonka   +2 more
semanticscholar   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.

Journal of Medicinal Chemistry, 1976
Deamino[4-threonine,8-D-arginine]vasopressin (dTDAVP), deamino[8-D-arginine]vasopressin (dDAVP), [8-D-arginine[vasopressin (DAVP), and deamino-arginine-vasopressin (dAVP) were synthesized by the solid-phase method and tested for their biological ...
M. Manning, L. Balaspiri, J. Moehring, J. Haldar, W. Sawyer   +4 more
semanticscholar   +3 more sources

Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.

New England Journal of Medicine, 1983
In a randomized double-blind cross-over trial we gave either 1-deamino-8-D-arginine vasopressin or placebo to 12 patients with uremia, hemorrhagic tendencies, and prolonged bleeding times.
P. Mannucci, G. Remuzzi, F. Pusineri, R. Lombardi, C. Valsecchi, G. Mecca, T. Zimmerman   +6 more
semanticscholar   +4 more sources

Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin

Collection of Czechoslovak Chemical Communications, 1967
M. Zaoral, J Kolc, F. Šorm
semanticscholar   +4 more sources

Plasma concentrations of 1-deamino-8-D-arginine vasopressin after intragastric administration in the rat.

Acta Endocrinologica, 1985
A sensitive and specific radioimmunoassay for 1-deamino-8-D-arginine vasopressin (DDAVP) was developed. Plasma concentrations of DDAVP after intragastric administration were determined in non-fasted rats and a dose-related increase in plasma levels was ...
S. Lundin, P. Melin, H. Vilhardt
semanticscholar   +4 more sources

Intranasal deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.

American Journal of Nephrology, 1984
Clinical bleeding in uremia is a frequent problem and seems to correlate with a prolonged bleeding time. The vasopressin analog deamino-8-D-arginine vasopressin has been shown to shorten the bleeding time and to decrease clinical bleeding when ...
M. Shapiro, S. Kelleher
semanticscholar   +4 more sources

Osmotic myelinolysis syndrome after treatment of severe deamino arginine vasopressin‐associated hyponatraemia: Pitfalls in emergency medicine

Emergency Medicine Australasia, 2007
AbstractHyponatraemia is among the more common electrolyte abnormalities encountered in the ED. Both the primary disturbance and its correction can result in life‐threatening neurological sequelae. Osmotic myelinolysis syndrome is one such complication and is associated with the rapid correction of hyponatraemia.
M. Gutenstein
semanticscholar   +3 more sources

L-deamino-8-d-Arginine Vasopressin Treatment in Pregnancy and Neonatal Outcome

American Journal of Perinatology, 1986
Three women with neurohypophyseal diabetes insipidus, treated for prolonged periods, including pregnancy, with L-deamino-8-d-arginine vasopressin, gave birth in our hospital. Two of the infants had severe congenital heart disease, one of which was associated with trisomy 21.
Nejama Linder, Israel Matoth, G. Ohel, Debora Yourish, Israel Tamir   +4 more
openalex   +4 more sources

Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease.

Pathophysiology of Haemostasis and Thrombosis, 1994
The synthetic agent, 1-deamino-8-D-arginine vasopressin (DDAVP), is generally regarded to be the treatment of choice for persons with type I von Willebrand disease (vWD), and may be useful in type IIA vWD as well.
J. Lusher
semanticscholar   +4 more sources